Condition: Primary Hyperlipidemia · Sponsor: Chengdu Diao Jiuhong Pharmaceutical Factory
Exploring the benefit risk ratio of increase in dosage of Zhibitai capsules (2 capsules at a time, 2 times a day) compared to the original dosage (1 capsule at a time, 1 day)
This description comes directly from the study's public registry record.
Jie Guo · +86 028-82900562 · guojie@rnd.diao.com
Always discuss trial participation with your own doctor first.
| Xiangya Second Hospital of Central South University | Changsha, Hunan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06822946